[LS-42] Luncheon Seminar 42 Treatment of generalized myasthenia gravis -new treatment to target FcRn-

[LS-42-1] A novel therapeutic drug, VYVGART: ADAPT study results and its application in real world clinical practice

^○Takamichi Sugimoto (Department of Neurology, Hiroshima University)